← Eichor
Study identifier: NCT04772937 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia

Condition: Cervical Dysplasia  ·  Sponsor: Ruhr University of Bochum

PhaseNA
Planned participants206
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia. The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).

This description comes directly from the study's public registry record.

Talk to the study team

Clemens B Temfper, MD, MBA  ·  +492323499  ·  clemens.tempfer@rub.de

Günther A Rezniczek, PhD  ·  +492323499  ·  guenther.rezniczek@rub.de

Always discuss trial participation with your own doctor first.

Locations (1)

Dept. OBGYN Ruhr University BochumHerne, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04772937